HIVE HIVE Digital Technologies Ltd Forecast, Technical & Fundamental Analysis

HIVE's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for HIVE moved out of overbought territory on September 25, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where HIVE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HIVE broke above its upper Bollinger Band on September 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HIVE just turned positive on September 09, 2025. Looking at past instances where HIVE's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for HIVE moved above the 200-day moving average on September 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 197 cases where HIVE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIVE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.473) is normal, around the industry mean (33.139). P/E Ratio (10.848) is within average values for comparable stocks, (73.016). HIVE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.186). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (4.132) is also within normal values, averaging (1514568.500).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.